Sensei Biotherapeutics reported a 2025 net loss of $21.1M with $21.2M cash, completing the Faeth acquisition and a $200M private placement to fund PIKTOR's Phase 2 endometrial and Phase 1b breast cancer trials through year-end 2026.
Key takeaways
Net loss was $21.1M, or $(16.72) per basic and diluted share, for the year ended December 31, 2025, compared to a net loss of $30.2M in 2024.
Cash, cash equivalents and marketable securities totaled $21.2 million as of December 31, 2025, down from $41.3 million as of December 31, 2024.
A $200 million private placement was completed concurrently with the acquisition of Faeth Therapeutics, adding PIKTOR as the lead program.
Phase 2 trial in advanced endometrial cancer (Study FTH-PIK-201) and planned Phase 1b trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101) are expected to report topline data by year-end 2026.
PIKTOR is an all-oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting.
Phase 1/2 trial of solnerstotug (VISTA inhibitor) in advanced solid tumors is ongoing.